Neuromeka Shares Slide 1.28% Amid Market Pullback, 200‑Day SMA Signals Bearish Trend
Neuromeka’s shares dip below their 200‑day SMA as Korean markets decline, yet the AI‑driven health & finance platform’s long‑term growth potential remains a key investor focus.
2 minutes to read